stockrow
Friday 6 November 2026
Export FBLG’s income statement to Excel — free account
FibroBiologics Inc.
FBLG Healthcare Biotechnology
- EPS
- +72.5%
- Free cash flow
- +21.6%
Quarter to June 2026, against a year earlier
0.97
0.01
+1.04%
Follow FBLG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | (2) | (5) | (16) | (11) | (19) | (18) | +85.3% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | (2) | (5) | (16) | (11) | (19) | (18) | +85.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (3.63) | (13.60) | (6.80) | (8.40) | (5.67) | +32.3% | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (2.88) | (4.53) | (7.24) | (7.34) | (2.36) | n/m | ||||||
| Capex | — | — | — | — | — | — | 0.00 | (0.35) | (0.11) | (0.12) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (2.88) | (4.89) | (7.35) | (7.46) | (2.36) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | (2.83) | 0.89 | 1.66 | 2.76 | 0.74 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 2 | 2 | 4 | +16.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (4) | (6) | (12) | (16) | (15) | +84.7% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | (27.2%) | ||||||
| Free cash flow | — | — | — | — | — | (1) | (4) | (7) | (12) | (17) | (15) | +85.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | (1) | (4) | 0 | 2 | 5 | 4 | n/m | |||||
| Net debt | — | — | — | — | — | 0 | (2) | (9) | (5) | (5) | (4) | +86.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | (1) | (4) | 1 | 3 | 6 | 5 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (193.54) | (228.99) | (78.97) | (143.08) | (166.14) | (143.1) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (824.53) | (932.71) | (824.5) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 193.76 | 1,389.57 | (559.73) | (419.44) | (660.08) | (419.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 10 | 10 | 13 | 15 | — | +14.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
FibroBiologics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMRN IMMURON | $6.9M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $6.6M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.4M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | |
| ENVB Enveric Biosciences, Inc. | $6.3M | — (loss-making) | — (loss-making) | −7.28% (below 0%: shrinking) | n/m | −29.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| APRE Aprea Therapeutics, Inc. | $6.2M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| AIM AIM ImmunoTech Inc. | $6.1M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| EVGN Evogene Ltd. | $6.0M | — (loss-making) | — (loss-making) | −35.02% (below 0%: shrinking) | n/m | +17.72% (above 0%: growing) | 40.63% | (738.62%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $5.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $6.3M | — | — | −35.02% | — | +6.25% | 76.47% | 0.00% |
Pay and ownership Proxy statement filed 31 July 2026
Ownership
Directors and executive officers, together
25.10%
Pete O’Heeron, MSHA
24.10%
Golden Knight Incorporated, L.P.
8.10%
Armistice Capital Master Fund Ltd.
8.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement